Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

References

• ReimerPChawlaSLong-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphomaJ Hematol Oncol201366924020452
   PubMed Web of Science ®Google Scholar
• FossFMZinzaniPLVoseJMGascoyneRDRosenSTTobinaiKPeripheral T-cell lymphomaBlood2011117256756676721493798
   PubMed Web of Science ®Google Scholar
• HamadaniMAbu KarSMUsmaniSZSavaniBNAyalaEKharfan-DabajaMAManagement of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomasSemin Hematol2014511738624468319
   PubMed Web of Science ®Google Scholar
• ReddyNMSavaniBNManagement of T-cell lymphomas: overcoming challenges and choosing the best treatmentSemin Hematol20145111424468310
   PubMed Web of Science ®Google Scholar
• ReddyNMEvensAMChemotherapeutic advancements in peripheral T-cell lymphomaSemin Hematol2014511172424468312
   PubMed Web of Science ®Google Scholar
• SchmitzNWuHSGlassBAllogeneic transplantation in T-cell lymphomasSemin Hematol2014511677224468318
   PubMed Web of Science ®Google Scholar
• GiuliaPCorradiniPAutologous stem cell transplantation for T-cell lymphomasSemin Hematol2014511596624468317
   PubMed Web of Science ®Google Scholar
• CorradiniPVitoloURambaldiAIntensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphomaLeukemia20142891885189124662801
   PubMed Web of Science ®Google Scholar
• YamaguchiMKitaKMiwaHFrequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cellsCancer19957611235123568635042
   PubMed Web of Science ®Google Scholar
• GottesmanMMMechanisms of cancer drug resistanceAnnu Rev Med20025361562711818492
   PubMed Web of Science ®Google Scholar
• KarlinLCoiffierBThe changing landscape of peripheral T-cell lymphoma in the era of novel therapiesSemin Hematol2014511253424468313
   PubMed Web of Science ®Google Scholar
• MarquardLPoulsenCBGjerdrumLMHistone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomasHistopathology200954668869819438744
   PubMed Web of Science ®Google Scholar
• MarquardLGjerdrumLMChristensenIJJensenPBSehestedMRalfkiaerEPrognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphomaHistopathology200853326727718671804
   PubMed Web of Science ®Google Scholar
• MolifeLRde BonoJSBelinostat: clinical applications in solid tumors and lymphomaExpert Opin Investig Drugs2011201217231732
   PubMed Web of Science ®Google Scholar
• RoperoSEstellerMThe role of histone deacetylases (HDACs) in human cancerMol Oncol200711192519383284
   PubMed Web of Science ®Google Scholar
• XuWSParmigianiRBMarksPAHistone deacetylase inhibitors: molecular mechanisms of actionOncogene200726375541555217694093
   PubMed Web of Science ®Google Scholar
• PiekarzRLFryeRPrinceHMPhase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood2011117225827583421355097
   PubMed Web of Science ®Google Scholar
• OlsenEAKimYHKuzelTMPhase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphomaJ Clin Oncol200725213109311517577020
   PubMed Web of Science ®Google Scholar
• DuvicMDummerRBeckerJCPanobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trialEur J Cancer201349238639422981498
   PubMed Web of Science ®Google Scholar
• GlaserKBHDAC inhibitors: clinical update and mechanism-based potentialBiochem Pharmacol200774565967117498667
   PubMed Web of Science ®Google Scholar
• BELEODAQ™ (belinostat) for injection [prescribing information]Henderson, NVSpectrum Pharmaceuticals, Inc2014
   Google Scholar
• NewMOlzschaHLa ThangueNBHDAC inhibitor-based therapies: can we interpret the code?Mol Oncol20126663765623141799
   PubMed Web of Science ®Google Scholar
• LemoineMYounesAHistone deacetylase inhibitors in the treatment of lymphomaDiscov Med2010105446247021122478
   PubMed Web of Science ®Google Scholar
• CoiffierBMonoclonal antibodies in the treatment of indolent lymphomasBest Pract Res Clin Haematol2005181698015694185
   PubMed Web of Science ®Google Scholar
• DuvicMTalpurRNiXPhase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood20071091313916960145
   PubMed Web of Science ®Google Scholar
• EllisLPanYSmythGKHistone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphomaClin Cancer Res200814144500451018628465
   PubMed Web of Science ®Google Scholar
• PohlmanBAdvaniRDuvicMFinal results of a Phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abstract]Blood200911422S379
   Web of Science ®Google Scholar
• O’ConnorOAMassziTSavageKJBelinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trialJ Clin Oncol201331Suppl absract 8507
   Google Scholar
• GimsingPBelinostat: a new broad acting antineoplastic histone deacetylase inhibitorExpert Opin Investig Drugs2009184501508
   PubMed Web of Science ®Google Scholar
• SteeleNLPlumbJAVidalLA phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumorsClin Cancer Res200814380481018245542
   PubMed Web of Science ®Google Scholar
• GimsingPHansenMKnudsenLMA phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasiaEur J Haematol200881317017618510700
   PubMed Web of Science ®Google Scholar
• SteeleNLPlumbJAVidalLPharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)Cancer Chemother Pharmacol20116761273127920706839
   PubMed Web of Science ®Google Scholar
• KellyWKYapTLeeJA Phase I Study of Oral Belinostat (PXD101) in Patients with Advanced Solid Tumors2007 ASCO Annual Meeting Proceedings2518S6 20 Supplement200714092
   Google Scholar
• ZainJMFossFKellyWKFinal results of a phase I study of oral belinostat (PXD101) in patients with lymphomaJ Clin Oncol20092715SSuppl absract 8580
   Google Scholar
• PlumbJAFinnPWWilliamsRJPharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101Mol Cancer Ther20032872172812939461
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNon-Hodgkin’s Lymphomas (Version 3.2014) Available at: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdfAccessed August 12, 2014
   Google Scholar